The total return over the past 12 months is +38.29% vs. +16.94% for the S&P 500. So far it's up -1.44% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +38.29% | +29.30% | (5.88%) | +14.53% | N/A | N/A |
| Total Return CAGR | +38.29% | +29.30% | (5.88%) | +14.53% | N/A | N/A |
| Revenue CAGR | +19.76% | +24.83% | +40.17% | +106.05% | +48.20% | +26.26% |
| Net Income CAGR | +418.03% | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | +448.84% | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | +87.80% | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | +87.47% | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Aurinia Pharmaceuticals Inc. (AUPH)
| Year | Start price | End price | AUPH Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $15.95 | $15.72 | (1.44%) | +14.51% | (15.95%) |
| 2025 | $8.98 | $15.95 | +77.62% | +17.72% | +59.90% |
| 2024 | $8.99 | $8.98 | (0.11%) | +24.89% | (25.00%) |
| 2023 | $4.32 | $8.99 | +108.10% | +26.19% | +81.91% |
| 2022 | $22.87 | $4.32 | (81.11%) | (18.17%) | (62.94%) |
| 2021 | $13.83 | $22.87 | +65.37% | +28.74% | +36.63% |
| 2020 | $20.26 | $13.83 | (31.74%) | +18.37% | (50.11%) |
| 2019 | $6.82 | $20.26 | +197.07% | +31.22% | +165.85% |
| 2018 | $4.53 | $6.82 | +50.55% | (4.56%) | +55.11% |
| 2017 | $2.10 | $4.53 | +115.71% | +21.70% | +94.01% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
